Literature DB >> 7408555

Susceptibility testing to trimethoprim alone and combined with sulphonamides.

K Dornbusch, L Gezelius.   

Abstract

In routine sensitivity testing by the disc diffusion methods, one member for each group of related antibiotics is chosen to represent the group. Each new antibacterial drug is evaluated with respect to its previous antibiotic class disc. In this study, trimethoprim combined with sulphadiazine in the ratio 1:4 was compared when combined with sulphamethoxazole in the ratio 1:20. Trimethoprim inhibited 86% of the bacterial strains tested at smaller than or equal to microgram/ml and the sulphonamides 50% of the strains at smaller than or equal to 64 microgram/ml. Regression line analysis showed that in sensitivity testing to trimethoprim alone discs with 5 micrograms can be used. Trimethoprim combined with sulphamethoxazole or sulphadiazine inhibited 84% respectively 91% of the strains at 0.5-8 microgram/ml. Trimethoprim combined with either sulphonamide produced superimposable regression lines. Therefore, sensitivity testing to trimethoprim/sulphadiazine can be performed by using discs with trimethoprim/sulphamethoxazole and the inhibition zone greater than or equal to 15 mm denotes susceptibility in the treatment of lower urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7408555     DOI: 10.1159/000237937

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

Review 1.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

2.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

3.  Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.

Authors:  H Goossens; P De Mol; H Coignau; J Levy; O Grados; G Ghysels; H Innocent; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

4.  In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.